相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cannabidiol and Beta-Caryophyllene in Combination: A Therapeutic Functional Interaction
Henry Blanton et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Prophylactic Administration of Cannabidiol Reduces Microglial Inflammatory Response to Kainate-Induced Seizures and Neurogenesis
Tanya R. Victor et al.
NEUROSCIENCE (2022)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience
Marie D'hooghe et al.
BMC NEUROLOGY (2021)
Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial
Sven G. Meuth et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2020)
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study
Francesco Patti et al.
NEUROLOGICAL SCIENCES (2020)
Treatment of Multiple Sclerosis: A Review
Stephen L. Hauser et al.
AMERICAN JOURNAL OF MEDICINE (2020)
Cannabis and multiple sclerosis
Yara Dadalti Fragoso et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2020)
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
Clare Walton et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial
Jolana Markova et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2019)
Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies
Katja Akguen et al.
JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE (2019)
Cannabinoids for Treatment of MS Symptoms: State of the Evidence
Jessica Rice et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2018)
Effect of tetrahydrocannabinol: cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study
Javier Mallada Frechin
NEURODEGENERATIVE DISEASE MANAGEMENT (2018)
Multiple sclerosis symptoms and spasticity management: new data
Guillermo Izquierdo
NEURODEGENERATIVE DISEASE MANAGEMENT (2017)
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients
Damiano Paolicelli et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Efficacy and safety of nabiximols (Sativex®) on multiple sclerosis spasticity in a real-life Italian monocentric study
Laura Ferre et al.
NEUROLOGICAL SCIENCES (2016)
Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis
Uwe K. Zettl et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2016)
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
F. Patti et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper
Susana Otero-Romero et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper
Susana Otero-Romero et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray
Tilden Etges et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2016)
Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice
Peter Flachenecker et al.
EUROPEAN NEUROLOGY (2014)
Nabiximols (THC/CBD Oromucosal Spray, Sativex (R)) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity
Peter Flachenecker et al.
EUROPEAN NEUROLOGY (2014)
Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis
Irene Moreno Torres et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2014)
Clinical experiences with cannabinoids in spasticity management in multiple sclerosis
L. Lorente Fernandez et al.
NEUROLOGIA (2014)
Clinical efficacy and effectiveness of Sativex®, a combined cannabinoid medicine, in multiple sclerosis-related spasticity
Celia Oreja-Guevara
Expert Review of Neurotherapeutics (2012)
Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids
Celia Oreja-Guevara
REVISTA DE NEUROLOGIA (2012)
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Kenneth F. Schulz et al.
BMC MEDICINE (2010)
Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration
Jan P. Vandenbroucke et al.
PLOS MEDICINE (2007)
Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption
Mohanraj Rajesh et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2007)
分享论文
